{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Objectives', 'Enpoints', 'To evaluate the effects of DTG/3TC FDC once', 'Change from Baseline in fasting lipids at Weeks', 'daily on fasting lipids over time compared to', '24 and 48', 'CAR', 'To assess viral resistance in participants', 'Incidence of observed genotypic and', 'meeting Confirmed Virologic Withdrawal (CVW)', 'phenotypic resistance to ARVs for participants', 'Criteria', 'meeting CVW Criteria', 'To assess health related quality of life for', 'Change from Baseline in health status using', 'participants treated with DTG/3TC FDC', 'HIV TSQ at Weeks 24 and 48 (or Withdrawal', 'compared to CAR', 'from the study) and SDM at Weeks 24, 48 and', 'every 24 weeks during the continuation phase', '(or Withdrawal from the study)', 'Exploratory', 'To assess willingness to switch for participants', 'Reasons for Willingness to Switch at Day 1', 'treated with DTG/3TC FDC compared to CAR', 'To evaluate renal (in urine and blood), bone (in', 'Change from Baseline in renal, bone and', 'blood), inflammatory (in blood) biomarkers and', 'inflammatory biomarkers and homeostasis', 'insulin resistance in participants treated with', 'model of assessment-insulin resistance (HOMA-', 'DTG/3TC FDC compared to CAR', 'IR) at Weeks 24 and 48', 'To evaluate biomarkers of telomerase function', 'Change from baseline in biomarkers of', 'in participants treated with DTG/3TC FDC', 'telomerase function at Week 48', 'compared to CAR.', '32']['2017N331008_06', 'CONFIDENTIAL', '208090', '4.', 'STUDY DESIGN', '4.1.', 'Overall Design', 'This is a 52-week, Phase III, randomized, open-label, active-controlled, multicenter,', 'parallel-group study to assess the non-inferior antiviral activity and safety of switching', 'from CAR to DTG/3TC FDC in adults living with HIV who are virologically suppressed', 'and stable on CAR. The study will include a Screening Phase (up to 28 days), a', 'Randomized Phase up to Week 52, and a Continuation Phase (post Week 52) (Section', '1.2). The Continuation Phase is not applicable for participants in Sweden and Denmark.', 'Approximately 490 adults living with HIV who are on a stable CAR will be randomized', '1:1 to switch to DTG/3TC FDC once daily for up to 52 weeks, or to continue their CAR', 'for 52 weeks. To control for treatment related factors that may impact study outcomes,', 'randomization will be stratified by baseline third agent class (protease inhibitor [PI],', 'integrase inhibitor [INI], or non-nucleoside reverse transcriptase inhibitor [NNRTI]). For', 'participants randomized to CAR, provisions will be in place, as needed and after', 'discussion with the study team, to assist participants in obtaining CAR during the study.', 'The primary endpoint for the study is the virologic failure endpoint as per FDA Snapshot', 'category at Week 48 using the Intent-to-Treat Exposed (ITT-E) population. The Week', '48 primary analysis will take place after the last participant has had their Week 48 viral', 'load assessed, including any retests. Participants randomized to DTG/3TC FDC will', 'receive DTG/3TC FDC up to Week 52.', 'All participants in the DTG/3TC FDC arm who successfully complete up to 52 weeks of', 'treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in a', 'Continuation Phase (See Section 4.3). Participants in the CAR arm will complete the', 'study at Week 52. The Continuation Phase is not applicable for participants in Sweden', 'and Denmark.', 'No dose reductions, modifications, or changes in the frequency of any components of', 'each regimen will be allowed during this study with the exception of a switch from a PI', 'boosted with ritonavir to the same PI boosted with cobicistat and vice versa. A switch', 'from lamivudine to emtricitabine and vice versa is also permitted. Protocol waivers or', 'exemptions are not allowed. Adherence to the study design requirements, including those', 'specified in the Schedule of Activities (Section 1.3), are essential and required for study', 'conduct. If deviations are required for the management of immediate safety concerns,', 'these should be communicated promptly to the study medical monitor.', 'An Independent Data Monitoring Committee (IDMC) will be instituted to ensure external', 'objective medical and/or statistical review of efficacy to protect the ethical interests and', 'well-being of participants and to protect the scientific validity of this study.', 'A sub-study of Virologic Response to Subsequent ART after Discontinuation from', '208090 for Meeting CVW or PVW Criteria will be conducted. Details are provided in', 'Section 11.2.', '33']\n\n###\n\n", "completion": "END"}